PPD forms new unit with Evidera, MARO teams

By Melissa Fassbender contact

- Last updated on GMT

PPD acquired Evidera last year. (Image: iStock/phive2015)
PPD acquired Evidera last year. (Image: iStock/phive2015)

Related tags: Scientific method

Pharmaceutical Product Development, LLC (PPD) has combined its medical affairs research operations (MARO) team and Evidera to create a dedicated real-world research and market access unit.

"This new, dedicated real-world research and market access unit will combine ​Evidera’s multidisciplinary scientific and consulting expertise to design studies, analyze findings and communicate outcomes, with PPD’s global operational infrastructure to manage and implement both interventional and observational studies​," Randy Buckwalter, a PPD spokesperson told Outsourcing-Pharma.com.

"The new unit will enable us to help our clients seamlessly integrate and align regulatory and post-approval research efforts, creating a smooth transition from Phase III to Phase IIIb/IV and real-world research, and improving their ability to meet the evidence demands of both regulators and payers​," he added.

PPD completed its acquisition of the evidence-based solutions provider, Evidera, in September of last year.

Jon Williams, who has served as the president and CEO of Evidera since 2013, told us at the time​ that both companies were committed to a seamless integration. 

The new dedicated unit will provide customers with various solutions, including modeling and simulation, interventional studies, observational studies, health economics, outcomes research, market access, epidemiology, real-world evidence, safety and risk management.

The new unit will retain the Evidera name and will be led by Williams.

Executive and scientific leadership of both Evidera and the medical affairs research operations organizations will also remain in place.

Related news

Show more

Related products

show more

Overcoming Challenges of Clinical Data Review

Overcoming Challenges of Clinical Data Review

PerkinElmer | 10-Jun-2021 | Technical / White Paper

Clinical data review is intrinsic to clinical development, assuring patient safety, determining drug efficacy, and assessing data quality. It involves...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 09-Jun-2021 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more